At the same time, findings from clinical trials contradict those from experimental studies, the latter of which demonstrate that GLP-1 RAs may prevent the onset of diabetic retinopathy or dampen its progression via anti-inflammatory and anti-apoptotic pathways, the paper said
Their development as useful therapeutics, however, has been limited by physiochemical properties that make them susceptible to metabolic degradation and impermeable to gut and blood-brain barriers
Any discussion of mechanisms or applications refers strictly to observations in non-human, preclinical research models
Protect a
[DOI] [PubMed] [Google Scholar] 86.Chen S., Wang J., Sun L., Xia F., Li W., Yuan L., Liu C., Li P., Bao C., Wang M., et al